• Report Adverse Event or Product Quality Complaint
  • US Site
  • Global Site
AstraZeneca Medical Information
  • Therapy Areas
    • All Therapeutic Areas
    • Cardiovascular
    • Immunology
    • Infection
    • Metabolic
    • Oncology
    • Renal
    • Respiratory
    • Rare Disease (Alexion)
  • Medications
  • Resources
    • Congress Library
    • Disease Education
    • Pipeline
    • Clinical Trials
    • Open innovation
    • Access 360
    • Affordability Programs
    • Sample Closet
    • Medical Education Grant
    • Rare Disease (Alexion)
  • Connect
    • Connect with Us
    • Find an MSL
    • Request an MSL
    • Submit an MIR
    • Give Feedback
User
  • Login to My AZmedical
  • Register for My AZmedical

Search Medical Information

Respiratory

AstraZeneca is pleased to present healthcare professionals with a variety of respiratory resources for your informational purposes.The educational materials are intended to provide disease-state information that can assist you in forming your own clinical and treatment decisions.

  1. Congress Library
  2. Medications
  3. Disease Education
  4. Continuing Education
  5. Pipeline

May 13 - 18, 2022

American Thoracic Society (ATS) 2022

Explore AstraZeneca Scientific Materials Visit Virtual Congress Site

February 25-28, 2022

American Academy of Allergy, Asthma & Immunology (AAAAI) Virtual Annual Meeting

Explore AstraZeneca Scientific Materials Visit Congress Site

November 4-8, 2021

American College of Allergy, Asthma & Immunology 2021 Annual Scientific Meeting

Explore AstraZeneca Scientific Materials Visit Congress Site

October 17-20, 2021

American College of Chest Physicians (CHEST) 2021 Annual Meeting

Explore AstraZeneca Scientific Materials Visit Congress Site

September 5-8, 2021

European Respiratory Society (ERS) 2021

Explore AstraZeneca Scientific Materials Visit Congress Site

May 14 - 19, 2021

American Thoracic Society (ATS) 2021

Explore AstraZeneca Scientific Materials Visit Virtual Congress Site

February 26 - March 1, 2021

American Academy of Allergy, Asthma and Immunology (AAAAI) Virtual Annual Meeting

Explore AstraZeneca Scientific Materials Visit Virtual Congress Site
  • BEVESPI AEROSPHERE® (glycopyrrolate and formoterol fumarate) inhalation aerosol
  • BREZTRI AEROSPHERE® (budesonide, glycopyrrolate, and formoterol fumarate) inhalation aerosol
  • DALIRESP® (roflumilast) Tablets
  • FASENRA® (benralizumab) injection, for subcutaneous use
  • PULMICORT FLEXHALER® (budesonide inhalation powder)
  • PULMICORT RESPULES® (budesonide inhalation suspension)
  • SYMBICORT® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol

e-learning

Cause for Alarm New Avenues to the Management of Severe Asthma

Integritas Communications

18-Jan-2022 to 18-Jan-2023

To better mirror real-world practice, this Case-in-Point™ severe asthma enduring program will utilize a case-based format to actively engage learners while emphasizing knowledge consolidation and translation

Learn More

e-Learning

PosterPerspectives: Research Developments in COPD from the 2021 Annual Meeting at the American College of Chest Physicians (“CHEST”)

Annenberg Center for Health Sciences at Eisenhower

12-Nov-2021 to 12-Nov-2022

Poster analysis from Chest 2021 (3 text modules reviewing 1 poster/abstract each)

Learn More

e-learning

On-demand- 2021 GOLD Conference

Integrity Continuing Education, Inc.

20-Dec-2021 to 20-Dec-2022

On-demand activity

Learn More

e-learning

Taking It From the Top: Targeting a New Approach to Controlling Severe Asthma

Medical Learning Institute Inc

17-Mar-2022 to 16-Apr-2023

• A 1.0 hour video learner-interactive online enduring activity & point-of-care practice tools

Learn More

e-Learning

Improving Patient Outcomes through Screening, Follow-Up and Treatment of Chronic Obstructive Pulmonary Disease

National Committee for Quality Assurance

15-Jan-2021 to 15-Jan-2023

2-hour recording with expert presentation and knowledge checks

Learn More

e-Learning

Epithelial Alarmins: A New Paradigm in Severe Asthma and Emerging Treatments

National Jewish Health

30-Jun-2022 to 30-Jun-2023

This educational activity focuses on the roles of epithelial alarmins, including TSLP, IL-33, and IL-25, as upstream mediators of the asthma inflammatory response and airway hyperresponsiveness.

Learn More

e-Learning

Reframing the Significance of Airway Hyperresponsiveness in Severe Asthma

National Jewish Health

27-May-2022 to 27-May-2023

The activity is focused on airway hyperresponsiveness, its clinical significance, and emerging treatments. The expert-guided material will provide practical tools for specialists.

Learn More

e-Learning

Clinical Implications of the Airway Epithelium on the Management of Patients with Severe Asthma

National Jewish Health

29-Apr-2022 to 29-Apr-2023

This educational activity will take a deep dive into the role of epithelial alarmins as upstream mediators of severe asthma's pathophysiology. It will also explore current and emerging therapies that target the epithelial alarmins.

Learn More

e-learning

COPD: Filling in the Gaps

Primary Care Education Consortium

04-Apr-2022 to 31-Mar-2023

The recording of the live presentation; archived webinar housed on the PCRG website. Each state chapter will promote the resource toolkit

Learn More

e-learning

Airway Inflammation Isn’t the Only Problem: Shining a Light on the Role of Airway Hyper-Responsiveness in Severe Asthma

PVI, PeerView Institute for Medical Education

27-May-2022 to 26-May-2023

0.5 credit hour learner-interactive online enduring activity & point-of-care practice tools

Learn More

e-learning

Tackling the Challenge of Treating Severe Asthma: Taking Aim at the Airway Epithelium

PVI, PeerView Institute for Medical Education

04-May-2022 to 03-May-2023

0.5 credit hour learner-interactive online enduring activity & point-of-care practice tools

Learn More

e-Learning

The Future of Severe Asthma Treatment Is Here: Expert Insights on the Rationale for Targeting Epithelial Alarmins

PVI, PeerView Institute for Medical Education, Inc.

17-Jun-2022 to 16-Jun-2023

0.50 credit hour learner-interactive online enduring activity & point-of-care practice tools

Learn More

Redirecting...

Welcome to AstraZeneca
Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am a payer or formulary decision-maker
I am neither (take me to AstraZeneca.com)
AstraZeneca Logo
Pharma Logo

This site is intended for healthcare professionals practicing in the US.

©2022 AstraZeneca. All rights reserved.

US-69609

Last Updated 11/22

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities

Survey Feedback

Your Privacy Choices

Privacy Notice

Legal Notice

Cookie Notice

US Site

Global Site

Report Adverse Event or Product Quality Complaint

Pharma Logo

Privacy NoticeLegal NoticeCookie Notice